Welcome to the project group page of Anette Weyergang: Recombinant Light Activated Therapeutics

Drug-based cancer therapy remains together with ionizing radiation and surgery one of the major cornerstones in cancer treatment. The recent years have revealed an impressive development in cancer therapeutics moving from conventional cytostatic drugs towards targeted therapeutics which opens the possibilities for personalized cancer treatment. Clinical benefit has indeed been shown for these new targeted therapeutics although they in general have failed to demonstrate complete remission of cancer. There is therefore still an unmet need for highly effective and selective drug-based anticancer modalities.

From left: Anette Weyergang, Ane Longva and Maria Berstad.